| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ... The Lancet 393 (10167), 156-167, 2019 | 1337 | 2019 |
| Identification of six new susceptibility loci for invasive epithelial ovarian cancer KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ... Nature genetics 47 (2), 164-171, 2015 | 307 | 2015 |
| Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores J Lecarpentier, V Silvestri, KB Kuchenbaecker, D Barrowdale, J Dennis, ... Journal of Clinical Oncology 35 (20), 2240-2250, 2017 | 191 | 2017 |
| Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 V Silvestri, D Barrowdale, AM Mulligan, SL Neuhausen, S Fox, BY Karlan, ... Breast Cancer Research 18, 1-13, 2016 | 145 | 2016 |
| Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification MT Parsons, E Tudini, H Li, E Hahnen, B Wappenschmidt, L Feliubadaló, ... Human mutation 40 (9), 1557-1578, 2019 | 119 | 2019 |
| Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families ND Kauff, P Perez-Segura, ME Robson, L Scheuer, B Siegel, A Schluger, ... Journal of Medical Genetics 39 (8), 611-614, 2002 | 116 | 2002 |
| Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification JM Sepúlveda-Sánchez, MÁ Vaz, C Balañá, M Gil-Gil, G Reynés, ... Neuro-oncology 19 (11), 1522-1531, 2017 | 103 | 2017 |
| BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers HD Meeks, H Song, K Michailidou, MK Bolla, J Dennis, Q Wang, ... Journal of the National Cancer Institute 108 (2), djv315, 2016 | 103 | 2016 |
| Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: Implications for genetic testing M de la Hoya, A Osorio, J Godino, S Sulleiro, A Tosar, P Perez‐Segura, ... International journal of cancer 97 (4), 466-471, 2002 | 95 | 2002 |
| A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01) C Balana, MA Vaz, J Manuel Sepúlveda, C Mesia, S Del Barco, E Pineda, ... Neuro-oncology 22 (12), 1851-1861, 2020 | 86 | 2020 |
| Extended-schedule dose-dense temozolomide in refractory gliomas A Berrocal, P Perez Segura, M Gil, C Balaña, J Garcia Lopez, R Yaya, ... Journal of Neuro-oncology 96, 417-422, 2010 | 71 | 2010 |
| Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer A Blanco, M de la Hoya, J Balmana, T Ramón y Cajal, A Teulé, ... Breast cancer research and treatment 132, 307-315, 2012 | 69 | 2012 |
| Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? A Manzano, P Pérez-Segura The Scientific World Journal 2012, 2012 | 65 | 2012 |
| Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers DG Cox, J Simard, D Sinnett, Y Hamdi, P Soucy, M Ouimet, L Barjhoux, ... Human molecular genetics 20 (23), 4732-4747, 2011 | 63 | 2011 |
| Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group … MJ Gil, R de Las Peñas, G Reynés, C Balañá, P Peréz-Segura, ... Anti-Cancer Drugs 23 (6), 659-665, 2012 | 62 | 2012 |
| Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology A Goday, I Barneto, JM García-Almeida, A Blasco, A Lecube, C Grávalos, ... Clinical and Translational Oncology 17, 763-771, 2015 | 59 | 2015 |
| Analysis of PALB2 Gene in BRCA1/BRCA2 Negative Spanish Hereditary Breast/Ovarian Cancer Families with Pancreatic Cancer Cases A Blanco, M de la Hoya, A Osorio, O Diez, MD Miramar, M Infante, ... PLoS One 8 (7), e67538, 2013 | 58 | 2013 |
| Prevalence of germline mutations of MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain T Caldes, J Godino, M de la Hoya, I Garcia Carbonero, P Perez Segura, ... International journal of cancer 98 (5), 774-779, 2002 | 58 | 2002 |
| A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families A Romero, P Pérez-Segura, A Tosar, JÁ García-Saenz, E Diaz-Rubio, ... Breast cancer research and treatment 129, 939-946, 2011 | 57 | 2011 |
| Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe E Le Rhun, R Rudà, P Devos, K Hoang-Xuan, D Brandsma, ... Journal of neuro-oncology 133, 419-427, 2017 | 56 | 2017 |
